Gentium Srl, founded in Milan in 2008, is a specialty pharmaceutical company dedicated to the research, development and commercialization of innovative therapies aimed at addressing rare and underserved medical conditions. Headquartered in Italy, the company operates state-of-the-art research and manufacturing facilities in northern Italy, leveraging a proprietary drug-delivery platform and expertise in formulation science to advance both small-molecule and biologic candidates.
The company’s product portfolio includes an approved intravenous therapy for the prevention and treatment of vascular complications in hematopoietic stem cell transplant patients, along with a pipeline of compounds in various stages of clinical development targeting inflammatory, hepatic and dermatologic disorders. In addition to its internally developed assets, Gentium Srl offers contract development and manufacturing services to biotechnology and medical device partners, providing end-to-end support from early-stage formulation through commercial supply.
Since its inception, Gentium Srl has forged strategic collaborations with leading academic institutions and contract research organizations across Europe, North America and the Asia-Pacific region. The company employs a hybrid commercialization model, marketing products directly in key European markets while leveraging licensing and distribution agreements to extend its global reach into the United States, Latin America and select Asian territories.
Under the leadership of Chief Executive Officer Dr. Andrea Ferraro—a seasoned pharmaceutical executive with over two decades of experience in orphan-drug development—and Chief Financial Officer Paola Rinaldi, Gentium Srl continues to strengthen its pipeline and expand partnerships. The management team remains focused on applying its technical know-how to bring novel therapeutic solutions to patients with high unmet medical needs.
AI Generated. May Contain Errors.
Free GENTY Stock Alerts